CClinicalTrials.gg
CompletedNCT00716131Updated Jan 6, 2017

Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program

An observational study in Amyotrophic Lateral Sclerosis, Neurodegenerative Disease and Motor Neuron Disease, sponsored by Drexel University College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-06.

Sponsored by Drexel University College of Medicine · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
205
Ages
18 Years and older
Sex
All
01

Study summary

Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases remains unknown. Effective treatment of these diseases are dependent on the elucidation of their causes. The availability of diseased and control human tissues will be a critical resource for this research progress. . Samples of serum, spinal fluid, and urine from patients with motor system diseases can be used to study biochemical and genetic differences compared to tissues of neurologic disease controls and normal controls. Furthermore, the availability of autopsied CNS, PNS, as well as other tissues from patients with ALS or suspected ALS are useful for current and future research studies into the disease. Therefore, we propose to institute a Tissue Bank containing blood, urine, and cerebrospinal fluid donated from not only ALS and other motor neuron disease patients, but also those with other neurologic diseases and normals whose tissue can be used as controls. In addition there will be an autopsy band for post-mortem specimens of ALS and other motor neuron disease patients. Each specimen, whether from a living patient or autopsy will be de-identified and accompanied by a standard set of clinical information collected from the medical records in order that each specimen is characterized with the relevant clinical information to maximize the usefulness of the specimens.

Once established, this tissue bank will provide a resource in which a large number of samples will be readily available and expedite research by circumventing the delays in collecting specimens prospectively. These specimens will be used for research in the ALS Center of Hope at Drexel University College of Medicine and shared with any outside investigator with a valid IRB approved protocol.

Read the detailed description

Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases remains unknown. Effective treatment of these diseases are dependent on the elucidation of their causes. The availability of diseased and control human tissues will be a critical resource for this research progress. . Samples of serum, spinal fluid, and urine from patients with motor system diseases can be used to study biochemical and genetic differences compared to tissues of neurologic disease controls and normal controls. Furthermore, the availability of autopsied CNS, PNS, as well as other tissues from patients with ALS or suspected ALS are useful for current and future research studies into the disease. Therefore, we propose to institute a Tissue Bank containing blood, urine, and cerebrospinal fluid donated from not only ALS and other motor neuron disease patients, but also those with other neurologic diseases and normals whose tissue can be used as controls. In addition there will be an autopsy band for post-mortem specimens of ALS and other motor neuron disease patients. Each specimen, whether from a living patient or autopsy will be de-identified and accompanied by a standard set of clinical information collected from the medical records in order that each specimen is characterized with the relevant clinical information to maximize the usefulness of the specimens.

Once established, this tissue bank will provide a resource in which a large number of samples will be readily available and expedite research by circumventing the delays in collecting specimens prospectively. These specimens will be used for research in the ALS Center of Hope at Drexel University College of Medicine and shared with any outside investigator with a valid IRB approved protocol.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Neurodegenerative Disease
  • Motor Neuron Disease

Keywords

  • Amyotrophic Lateral Sclerosis
  • Cerebrospinal Fluid
  • Neurodegenerative Disease
  • Motor Neuron Disease
  • Autonomic Nervous System
  • Neurodegenerative Diseases
  • Movement Disorders
03

In context

Motor Neuron Disease

717 studies on the registry are indexed under Motor Neuron Disease; 137 are open to participants now.

This study's enrollment of 205 is above the median of 109 across 217 observational studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Drexel University College of Medicine is the lead sponsor of 26 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

ALS clinic patients at MDA/ALS Center of Hope, along with families and caregivers. Also those with ALS who have donated their bodies to research.

Inclusion criteria

  • Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
  • Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
  • Normal Controls
  • In the case of spinal fluid collection, the patient will be undergoing a diagnostic lumbar puncture as part of the work-up

Exclusion criteria

Exclusion Criteria:

  • Any person with a non-neurologic chronic and poorly controlled systemic illness
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
205 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • ALS

    Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy

  • Neuro

    Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)

  • Healthy

    Normal Controls

  • Autopsy
06

What researchers measure

Primary outcomes

  1. None Specified

    No primary outcome measure is specified for this study. Purpose of the study is to collect deidentified biological specimens which will be used to expedite other IRB approved studies.

    Time frame: None Specified

07

Study locations

1 site
  • MDA/ALS Center of Hope
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: No — The purpose of this protocol is to collect and bank tissue specimens.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00716131
Lead sponsor
Drexel University College of Medicine
Collaborators
MDA/ALS Center of Hope
Responsible party
Christine Barr (Research Nurse Coordinator, Drexel University) — Principal investigator
First posted
Jul 16, 2008
Start date
Apr 2007
Primary completion
Nov 2016
Completion
Nov 2016
Last update
Jan 6, 2017

Study contacts

Terry D Heiman-Patterson, MD
principal investigator · Drexel University College of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion